How we used behavioural economic theory to reveal fresh insights into patient compliance
Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.
However, sales data suggests that repeat prescriptions drastically reduce after the first 3-6 months. Although the product has a known SE profile, our client believes that this can be well managed and controlled.
How we assessed the access potential of a new product in order to develop a successful launch strategy
Our client had two regimens in clinical development for the front-line treatment of an oncology condition using a breakthrough product; and planned to release outcomes data at key industry events throughout the year.
To ensure a fast and successful launch they wanted to develop key strategies to maximise acceptance and reimbursement of their product amongst HCPs and Payers.
How we facilitated mock negotiations with payers to improve the pricing strategy for a new biologic in Latin America
Our client wanted to understand how they should manage payer objections within the value proposition, clinical evidence and economic value of the product.
At offered prices, it would be cost-effective and have comparable / lower net budget impact than analogues. However, payers in Latin America were still expected to add further barriers or reject the reimbursement request. As a result our client wanted to understand how they should manage payer objections within the value proposition, clinical evidence and economic value of the product.
How we assessed payer perceptions of a new therapy for Atopic Dermatitis in emerging markets
Our client was developing a product for use in treating a number of indications including Atopic Dermatitis (AD); and wanted to understand how best to position this product in order to optimise pricing and market access.
Market research was required to understand payer perceptions of the AD market, and the pricing and reimbursement opportunities in emerging markets.
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and successfully differentiate it against their closest competitor.Communication strategies and marketing messages were to be crafted using the outcomes data which our client planned to launch at the European Society of Cardiology (ESC) annual congress. As a result, our client wanted to understand in detail the impact of their data on physicians’ perceptions of them.